Free Trial
NYSEAMERICAN:VNRX

VolitionRx (VNRX) Stock Price, News & Analysis

VolitionRx logo
$0.51 +0.02 (+3.77%)
As of 05/30/2025 04:10 PM Eastern

About VolitionRx Stock (NYSEAMERICAN:VNRX)

Key Stats

Today's Range
$0.48
$0.52
50-Day Range
$0.42
$0.57
52-Week Range
$0.40
$0.90
Volume
242,916 shs
Average Volume
179,863 shs
Market Capitalization
$32.00 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.

Receive VNRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for VolitionRx and its competitors with MarketBeat's FREE daily newsletter.

VNRX Stock News Headlines

Trump Exec Order 14179 is wealth “gift” to good Americans?
Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve suffered financial hardship…Our President may have solved everything.
VolitionRX Q1 2025 Earnings Preview
See More Headlines

VNRX Stock Analysis - Frequently Asked Questions

VolitionRx's stock was trading at $0.58 at the start of the year. Since then, VNRX stock has decreased by 12.7% and is now trading at $0.5065.
View the best growth stocks for 2025 here
.

VolitionRx Limited (NYSEAMERICAN:VNRX) posted its quarterly earnings data on Wednesday, November, 10th. The medical research company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.11) by $0.02. The medical research company had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.03 million. VolitionRx had a negative net margin of 9,158.31% and a negative trailing twelve-month return on equity of 15,493.47%.

Shares of VNRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that VolitionRx investors own include Chesapeake Energy (CHKAQ), Bausch Health Companies (BHC), Avino Silver & Gold Mines (ASM), Avino Silver & Gold Mines (ASM), Exelixis (EXEL), T2 Biosystems (TTOO) and Gilead Sciences (GILD).

Company Calendar

Last Earnings
11/10/2021
Today
5/31/2025
Next Earnings (Estimated)
8/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSEAMERICAN
Sector
Medical
Industry
Diagnostics & Research
Sub-Industry
Pharmaceutical Products
Current Symbol
NYSEAMERICAN:VNRX
Previous Symbol
NYSEMKT:VNRX
Employees
80
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$30.27 million
Net Margins
-9,158.31%
Pretax Margin
-9,257.43%
Return on Equity
-15,493.47%

Debt

Sales & Book Value

Annual Sales
$310,000.00
Price / Cash Flow
N/A
Book Value
($0.05) per share
Price / Book
-10.13

Miscellaneous

Free Float
53,450,000
Market Cap
$32.00 million
Optionable
Not Optionable
Beta
1.59
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

This page (NYSEAMERICAN:VNRX) was last updated on 5/31/2025 by MarketBeat.com Staff
From Our Partners